Compare AREC & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AREC | LCTX |
|---|---|---|
| Founded | 2013 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 376.4M | 407.7M |
| IPO Year | 2019 | N/A |
| Metric | AREC | LCTX |
|---|---|---|
| Price | $3.58 | $1.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $6.50 | $4.25 |
| AVG Volume (30 Days) | ★ 4.0M | 1.2M |
| Earning Date | 02-18-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $95,026.00 | ★ $10,816,000.00 |
| Revenue This Year | N/A | $6.32 |
| Revenue Next Year | $42,083.44 | $124.49 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 24.05 |
| 52 Week Low | $0.38 | $0.37 |
| 52 Week High | $7.11 | $2.09 |
| Indicator | AREC | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 62.34 | 46.77 |
| Support Level | $3.25 | $1.64 |
| Resistance Level | $3.76 | $1.79 |
| Average True Range (ATR) | 0.30 | 0.09 |
| MACD | 0.10 | -0.00 |
| Stochastic Oscillator | 86.25 | 34.62 |
American Resources Corp constructs and/or purchases and manages a chain of combined gasoline, diesel and natural gas (NG) fueling and service stations; construct conversion factories to convert NG to liquefied natural gas (LNG) and compressed natural gas (CNG); and construct conversion factories to retrofit vehicles currently using gasoline or diesel fuel to also run on NG in the United States and also to build a convenience store to serve its customers in each of its locations. Its segments are AIC focused on the extraction, processing, transportation, and distribution of coal for a variety of industries, with a focus on metallurgical quality coal to the steel industry; RLMT; and EMC.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.